Brief: Mirum Pharmaceuticals Receives Paragraph IV Notice From Sandoz On Livmarli - SEC Filing
17/11/2025 22:04
Nov 17 (Reuters) - Mirum Pharmaceuticals Inc MIRM.O: MIRUM PHARMACEUTICALS INC - RECEIVES PARAGRAPH IV NOTICE FROM SANDOZ ON LIVMARLI - SEC FILING MIRUM PHARMACEUTICALS INC - SANDOZ ALLEGES FIVE LIVMARLI PATENTS INVALID OR UNENFORCEABLE - SEC FILING MIRUM PHARMACEUTICALS INC - TO FILE PATENT INFRINGEMENT SUIT AGAINST SANDOZ - SEC FILING Further company coverage: MIRM.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mirum Pharmaceuticals
See all newsMirum Pharmaceuticals Q3 net product sales surge, outlook raised
Brief: Mirum Pharmaceuticals Announces Positive Results From Cohort 2 Of The Pivotal Progress Study Of Atebrioz™ (Zilurgisertib) In Pediatric Patients Aged 6 To <12 Years With Fibrodysplasia Ossificans Progressiva
Mirum climbs on positive late-stage trial results for liver disease drug
US STOCKS ON THE MOVE-Mirum Pharmaceuticals, Meta, Boeing
U.S. STOCKS ON THE MOVE-Royal Caribbean Cruises, SpaceX